AI tools don't equal guaranteed drug success as BenevolentAI flops dermatitis test

Kyle LaHucik

Associate Editor

It’s a no for BEN.

BEN-2293, a topical out of London-based BenevolentAI, has failed secondary efficacy measures in a Phase IIa study in atopic dermatitis. The investigational drug, one of an early generation drummed up by the buzzy AI tools in biotech, works by inhibiting multiple tropomyosin-related kinases, which are known best in the cancer landscape with Bayer’s Vitrakvi and Roche’s Rozlytrek.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

AI tools don't equal guaranteed drug success as BenevolentAI flops dermatitis test

Kyle LaHucik

Associate Editor

To read Endpoints News become a free subscriber

Who pays the most (and least) in biopharma? We crunched median salary data from 175 companies

After gene therapy deaths, Astellas to revisit fatal neuromuscular condition in partnership with biotech startup

Upstream Bio matches first funding round with another $200M to get asthma drug to PhIII

FDA commissioner says drug prices are too high, calls for better evidence generation

4DMT's inhalable gene therapy for cystic fibrosis shows early positive signs in tiny group of patients

The new rules of cancer care: Responding to increasing CMS influence on the oncology landscape

AI tools don't equal guar­an­teed drug suc­cess as Benev­o­len­tAI flops der­mati­tis test

Kyle LaHucik

Associate Editor

To read Endpoints News become a free subscriber

Who pays the most (and least) in bio­phar­ma? We crunched me­di­an salary da­ta from 175 com­pa­nies

Af­ter gene ther­a­py deaths, Astel­las to re­vis­it fa­tal neu­ro­mus­cu­lar con­di­tion in part­ner­ship with biotech start­up

Up­stream Bio match­es first fund­ing round with an­oth­er $200M to get asth­ma drug to PhI­II

FDA com­mis­sion­er says drug prices are too high, calls for bet­ter ev­i­dence gen­er­a­tion

4DMT's in­hal­able gene ther­a­py for cys­tic fi­bro­sis shows ear­ly pos­i­tive signs in tiny group of pa­tients

The new rules of can­cer care: Re­spond­ing to in­creas­ing CMS in­flu­ence on the on­col­o­gy land­scape

AI tools don't equal guaranteed drug success as BenevolentAI flops dermatitis test

Who pays the most (and least) in biopharma? We crunched median salary data from 175 companies

After gene therapy deaths, Astellas to revisit fatal neuromuscular condition in partnership with biotech startup

Upstream Bio matches first funding round with another $200M to get asthma drug to PhIII

FDA commissioner says drug prices are too high, calls for better evidence generation

4DMT's inhalable gene therapy for cystic fibrosis shows early positive signs in tiny group of patients

The new rules of cancer care: Responding to increasing CMS influence on the oncology landscape